大体积非小细胞肺癌采用双野稳健质子晶格加量后常规放化疗
本文报告两例大体积非小细胞肺癌患者,接受新型双野部分稳健笔束扫描质子晶格加量12 Gy后再行标准常规放化疗。两例患者仅出现常见轻度治疗相关毒性,大体积病灶在治疗一年多后仍获野内控制。
要点
- 双野部分稳健质子晶格加量12 Gy后接常规放化疗方案可行。
- 两例患者仅出现常见轻度治疗相关毒性。
- 治疗一年多后大体积病灶仍保持野内控制。
核心结论
- 双野部分稳健质子晶格加量联合常规放化疗在大体积非小细胞肺癌中显示可行性和早期控制信号。
研究设计与样本
- 两例大体积非小细胞肺癌病例报告,采用新型双野部分稳健笔束扫描质子晶格加量12 Gy后行标准常规放化疗。
主要发现
- 两例患者均出现常见轻度治疗相关毒性。
- 两例患者大体积病灶在治疗一年多后仍获野内控制。
关键数值与推荐
- 质子晶格加量剂量为12 Gy。
- 加量后接标准常规放化疗。
临床怎么用
- 可考虑将双野部分稳健质子晶格加量整合入大体积非小细胞肺癌的根治性治疗。
局限性
- 仅为两例病例报告,样本量小,无法评估疗效和毒性的普遍性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Despite advances in outcomes for non-small cell lung cancer (NSCLC) with the establishment of adjuvant immunotherapy as the standard of care, locoregional recurrence is still experienced by half of patients with progressive disease. We sought to integrate a novel pencil beam scanning (PBS) spatially fractionated approach into definitive management of bulky non-small cell lung cancer cases. Spatial fractionation via lattice or more commonly GRID has long been of interest as supplement to more conventional radiation regimens for bulky tumors, though requirements for plan robustness and concerns about single-field approaches have previously limited their integration into proton therapy practice. Here we present two cases of bulky NSCLC treated with a novel two-field partially robust PBS lattice boost of 12 Gy followed by standard conventional chemoradiation. Both patients experienced usual mild treatment related toxicities and remain with their bulky lesions controlled in field at more than a year out from treatment.
引用
- Ferris MJ, Mossahebi S, Jatczak J, et al. Bulky non-small cell lung cancer treated with two-field robust proton lattice boost followed by conventional chemoradiation. Clin Transl Radiat Oncol. 2025. PMID: 40612358. doi:10.1016/j.ctro.2025.100987
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。